Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome

Study:

A Phase II Trial of Ethyol (Amifostine) in Adult Patients With Advanced Myelodysplastic Syndromes

Rationale:

Amifostine may be effective in helping blood counts return to normal in treating patients with myelodysplastic syndrome.

Purpose:

Phase II trial to study the effectiveness of amifostine in treating patients with advanced myelodysplastic syndrome.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Myelodysplastic Syndromes Drug: amifostine trihydrate Phase 2

Verified by Providence Cancer Institute at Providence Hospital - Southfield Campus January, 2004

Sponsored by: Providence Cancer Institute at Providence Hospital - Southfield Campus
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00003123

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States

Howard R. Terebelo, DO., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site